MapLight Therapeutics, Inc.

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. The company operates a proprietary platform designed to identify neural circuits causally linked to disease states, with the goal of enabling targeted therapeutic modulation. This approach underpins its pipeline of muscarinic receptor agonists, G-protein-coupled receptor modulators, and related compounds.

The company's product candidates address multiple therapeutic areas. ML-007C-MA, a fixed-dose combination M1/M4 muscarinic agonist, is in development for schizophrenia and Alzheimer's disease psychosis. ML-004 targets social communication deficits and irritability associated with autism spectrum disorder. ML-021 is being developed for motor deficits in Parkinson's disease, while ML-009, a GPR52 positive allosteric modulator, addresses hyperactivity, impulsivity, and agitation-related disorders.

Based in Redwood City, California, MapLight operates with approximately 114 full-time employees. As a clinical-stage enterprise, the company has not yet generated significant product revenues. The company was incorporated in Delaware in 2018 and adopted its current name in August 2019, having previously operated as Alvarado Therapeutics.